It has been found that the level of expression of the CTLA-4 gene in CLL cells is a reliable indicator predicting survival and treatment requirements for CLL patients, since its higher activity in these cells is associated with good clinical outcome, and its lower expression is correlated with a significantly short time to treatment and poor prognosis [19]. This evidence concerns the gene CTLA4 and B-cell chronic lymphocytic leukemia.